Come Join Me
Excited about DIA's Global Annual Meeting in Washington DC. I'll be leading a panel on June 16 about how biopharma, regulators and payers are using RWE and on June 17 at the Executive Day session on "RWE Applications - Knowing when they work and when they don't."
Seasoned leader with experience using real-world evidence to improve health
Nancy A. Dreyer, MPH, PhD, FISPE
Serial Entrepreneur
Demonstrated Business Success Expert in Real-World Evidence
Nancy Dreyer is Adjunct Professor of Epidemiology at the University of North Carolina at Chapel Hill, Chief Scientific Officer Emeritus at IQVIA Real World Solutions, and a Trustee of Brandeis University. Well-known for her thought leadership, she has helped advance the use of real-world evidence for clinical decision support and regulatory purposes, influencing the content of guidelines by regulators in the US, Europe, and China, each of which cite one or more of her publications. Her experience includes biopharmaceutical, occupational and environmental research.
​
Her substantial executive and field experience have helped hone her pragmatic views.
Profile overview
Areas of expertise
Education & Honors
Recent External highlights
35+ years of experience in epidemiology and business including​
-
IQVIA, SVP and Chief Scientific Officer
-
Quintiles/Outcome Sciences Inc, SVP, Chief of Scientific Affairs
-
i3 Research/Ingenix, UnitedHealth Group, SVP
-
Epidemiology Resources, Inc. and the New England Epidemiology Institute, CEO & Chair of the Board
-
Developing reliable real-world evidence (RWE) derived from person-generated health data, electronic medical records and/or pharmacy and medical claims
-
Regulatory use of RWE for market authorization and label expansion
-
Assessing the relevance and reliability of RWE for decision support
-
Health and mortality data linkage
-
BA, Brandeis University
-
Master of Public Health, Epidemiology, University of North Carolina
-
PhD, Epidemiology, University of North Carolina
-
Fellow, International Society of Pharmacoepidemiology
-
Fellow, Drug Information Association
-
Brandeis University, Trustee
-
Drug Information Association, Scientific & Policy Advisory Council and former Director
-
Duke-Margolis Center for Health Policy Research Planning Board
-
OM1, Chief, Scientific Advisory Board
-
University of North Carolina Gillings School of Public Health, Adjunct Professor of Epidemiology,
Selected Recent Publications
-
Riskin D, Monda KL, Gagne JJ, Reynolds R, Garan AR, Dreyer N, Muntner P, Bradbury B. Data Reliability: Implementation of accuracy, completeness, and traceability. JAMA Open 2025;8(3):e250128. doi:10.1001/jamanetworkopen.2025.0128
-
Hernandez RK, Critchlow CW, Dreyer N et al. Advancing Principled Pharmacoepidemiologic Research to Support Healthcare Decision-Making: The Era of Real-world Evidence. Clinical Pharmacology & Therapeutics 2025. https://doi.org/10.1002/cpt.3563
-
Dreyer NA and Blackburn SCF. Power to the people: Why person-generated health data is important for pharmacoepidemiology. American Journal of Epidemiology 2024: https://doi.org/10.1093/aje/kwae035
-
Dreyer NA et al. COVID-19 vaccination reactions and risk of breakthrough infections among people with diabetes: cohort study derived from community reporters. JMIR Diabetes 2024; e45536, https://diabetes.jmir.org/2024/1/e45536/ doi: 10.2196/45536
-
Dreyer NA, Mack CD. Tactical considerations for designing real-world studies: Fit-for-purpose designs that bridge research and practice. Pragmatic and Observational Research 2023:14 101–110
-
Largent JA, Xie X...and Dreyer NA. Cognitive and other neuropsychiatric symptoms in COVID-19: Analysis of person-generated longitudinal health data from a community-based registry, BMJ Open 2023 ;13:e069118. doi:10.1136/ bmjopen-2022-069118
-
Dreyer NA. Strengthening evidence-based medicine with real-world evidence. Invited Commentary. Lancet Healthy Longevity 2022 Oct;3(10):e641-e642. doi: 10.1016/S2666-7568(22)00214-8. Epub 2022 Sep 20. PMID: 36150401.